Return to Travel in the Coronavirus Disease 2019 Pandemic Recovery Period and Implications for Imported Malaria: Reinforcing Prevention, Early Diagnosis, and Appropriate Treatment of Malaria

Clin Infect Dis. 2023 Apr 3;76(7):1161-1163. doi: 10.1093/cid/ciad061.

Abstract

Return to international travel in the COVID-19 pandemic recovery period is expected to increase the number of patients with imported malaria in the United States (US). Malaria prevention in travelers and preparedness for timely diagnosis and appropriate treatment are key to minimize imported malaria morbidity and mortality. Intravenous artesunate (IVAS) is now available from commercial distributors in the US for the treatment of severe malaria. Hospitals and pharmacists should have a plan for malaria treatment, including stocking artemether-lumefantrine for uncomplicated malaria, and stocking or planning for rapid procurement of IVAS for the treatment of severe malaria.

Keywords: Plasmodium falciparum; artesunate; chemoprophylaxis; malaria; travel.

MeSH terms

  • Antimalarials* / therapeutic use
  • Artemether / therapeutic use
  • Artemether, Lumefantrine Drug Combination / therapeutic use
  • Artesunate / therapeutic use
  • COVID-19 Testing
  • COVID-19*
  • Early Diagnosis
  • Humans
  • Malaria* / diagnosis
  • Malaria* / drug therapy
  • Malaria* / prevention & control
  • Malaria, Falciparum* / drug therapy
  • Pandemics / prevention & control
  • Travel
  • United States / epidemiology

Substances

  • Antimalarials
  • Artemether
  • Artemether, Lumefantrine Drug Combination
  • Artesunate